Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Incorporated remains a buy ... Alyftrek's launch extends Vertex's CF leadership, patent life, and addressable market, while Casgevy and Journavx add new growth avenues.

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

Let's take a look at some of them. Its secret sauce: Getting to the underlying cause Vertex Pharmaceuticals made a fortune thanks to its CF franchise for two reasons. First, it developed medicines ...

Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX).The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Brian Skorney’s ‘Hold’ rating for Vertex Pharmaceuticals is largely influenced by a blend of factors. Firstly, the company’s cystic fibrosis (CF) franchise continued to exhibit solid ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Phil Nadeau from TD Cowen maintained a Buy rating on the ...